Charles River Laboratories International (NYSE:CRL) Given Outperform Rating at William Blair

Charles River Laboratories International (NYSE:CRL)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a report issued on Tuesday,Benzinga reports.

Other analysts have also recently issued research reports about the stock. UBS Group increased their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Trading Down 6.3 %

Charles River Laboratories International stock traded down $12.03 during trading on Tuesday, reaching $178.11. 1,050,715 shares of the company were exchanged, compared to its average volume of 671,818. The stock’s 50 day simple moving average is $193.57 and its two-hundred day simple moving average is $199.32. The company has a market capitalization of $9.11 billion, a P/E ratio of 22.29, a PEG ratio of 5.00 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International has a 52-week low of $175.61 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the previous year, the firm earned $2.72 EPS. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Charles River Laboratories International by 24.6% during the 2nd quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock worth $170,615,000 after buying an additional 163,056 shares during the last quarter. 1832 Asset Management L.P. acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $33,053,000. Finally, Earnest Partners LLC boosted its holdings in shares of Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after buying an additional 110,725 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).